• Title of article

    Design and synthesis of nitrate esters of aromatic heterocyclic compounds as pharmacological preconditioning agents Original Research Article

  • Author/Authors

    Theano Fotopoulou، نويسنده , , Efstathios K. Iliodromitis، نويسنده , , Maria Koufaki، نويسنده , , Andrew Tsotinis، نويسنده , , Anastasia Zoga، نويسنده , , Vassilis Gizas، نويسنده , , Anastasia Pyriochou، نويسنده , , Andreas Papapetropoulos، نويسنده , , Ioanna Andreadou، نويسنده , , Dimitrios Th. Kremastinos، نويسنده ,

  • Issue Information
    روزنامه با شماره پیاپی سال 2008
  • Pages
    9
  • From page
    4523
  • To page
    4531
  • Abstract
    Ischemic preconditioning (IPC) constitutes an endogenous protective mechanism in which one or more brief periods of myocardial ischemia and reperfusion render the myocardium resistant to a subsequent more-sustained ischemic insult. Pharmacological preconditioning represents an ideal alternative of IPC. We now describe the design and synthesis of indole, quinoline, and purine systems with an attached pharmacophoric nitrate ester group. The indole and quinoline derivatives 4 and 5 possess structural features of the nitrate containing KATP channel openers. Purine analogues 11 and 12, substituted at the position 6 by a piperidine moiety and at position 9 by an alkyl nitrate, could combine the effects of the nitrate containing KATP channel openers and those of adenosine. Compound 13 bears the nicotinamide moiety of nicorandil instead of nitrate ester. Compounds 4, 5, and 11 reduced infarction and the levels of malondialdehyde (MDA) at reperfusion in anesthetized rabbits. Compounds 12 and 13 did not significantly reduce the infarct size. Analogues 4 and 5 increased cGMP and MDA during ischemia, while combined analogue 4 and mitoKATP blocker 5-hydroxydecanoic acid (5-HD) abrogated this benefit suggesting an action through mitoKATP channel opening. Treatment with derivative 11 combined with 5-HD as well as treatment with 11 and adenosine receptor blocker 8-(p-sulfophenyl)theophylline (SPT) did not abrogate cardioprotection. Compound 11 is a lead molecule for the synthesis of novel analogues possessing a dual mode of action through cGMP–mitoKATP channel opening-free radicals and through adenosine receptors.
  • Keywords
    Pharmacological preconditioning , KATP channel openers , Adenosine , Infarct size
  • Journal title
    Bioorganic and Medicinal Chemistry
  • Serial Year
    2008
  • Journal title
    Bioorganic and Medicinal Chemistry
  • Record number

    1304276